Repurposed Cancer Drugs, Integrative & Precision Oncology (2026): Evidence Guide

An evidence-aware guide to off-label cancer therapies, integrative oncology, precision oncology and emerging research, without hype or false promises.

By Dr. Frank Yap, MD · One Day Media Network · Originally published January 2026 · Updated October 6, 2026 · Evidence reviewed to this date

Quick Answer

Repurposed cancer drugs are existing approved medicines tested for anti-cancer effects. As of October 2026, only one has recent randomized-trial support in a defined setting: low-dose aspirin after surgery for PI3K-pathway-altered stage I–III colorectal cancer (ALASCCA, NEJM 2025). Metformin failed in the 3,649-patient MA.32 breast cancer trial. Ivermectin, fenbendazole and mebendazole have no completed randomized trials showing cancer benefit. Repurposed drugs are adjuncts to, never replacements for, standard oncology care.

Contents

What This Hub Covers

This page is the central hub for OneDayMD's coverage of repurposed drugs and precision oncology. It explains:

  • What repurposed drugs are, and what they are not.
  • Which drugs show credible anti-cancer signals and which remain speculation.
  • How repurposed therapies may (or may not) fit alongside standard oncology.
  • The evidence hierarchy used across OneDayMD.
  • Safety, ethics and regulatory realities, including ASCO's 2026 guidance.

It is written for patients, caregivers, clinicians and researchers who want clarity rather than promotion.

Executive Summary

Repurposed drugs in cancer care are existing, approved medications originally developed for non-cancer indications that show potential anti-cancer effects through epidemiological signals, mechanistic pathways, real-world data or early clinical trials. Interest has grown because of rising cancer incidence, plateauing outcomes in late-stage disease, high oncology drug costs, and advances in systems biology and AI-driven drug discovery.

This pillar offers a structured, evidence-graded framework for judging these drugs without hype or dismissal. Three conclusions stand out in 2026:

  1. The best evidence is narrow and biomarker-selected. The clearest success is aspirin in PI3K-altered colorectal cancer, not a blanket “aspirin fights cancer” claim.
  2. Strong observational signals can fail in randomized trials. Metformin is the cautionary example.
  3. Popular antiparasitic protocols remain unproven in humans, and professional oncology guidance has hardened against unsupervised use.

Diagram of cancer hallmarks targeted by repurposed non-oncology drugs

Cancer hallmarks targeted by repurposed non-oncology drugs. Figure created with Biorender.com. Source: Nature (Signal Transduction and Targeted Therapy), 2024.

Why Repurposed Drugs Matter in Oncology

1. The economic and clinical reality

  • Novel oncology drugs frequently exceed $100,000 per year in list price.
  • Median survival benefits in advanced cancers are often measured in months.
  • Many repurposed drugs are off-patent, inexpensive and globally available, which also means few companies fund large trials of them.

2. Biology has outpaced drug development

Cancer is increasingly understood as a systems disease involving metabolic dysregulation, immune evasion, inflammation, microbiome interactions and mitochondrial dysfunction. Classic chemotherapy mainly targets cell division, leaving other hallmarks unaddressed.

3. Real-world evidence generates hypotheses, not proof

Observational data repeatedly show unexpected cancer outcomes in people taking certain non-oncology drugs. These signals justify trials. They do not justify treatment decisions on their own, because confounding (healthier patients, earlier diagnosis, adherence effects) is common.

Evidence Scale Used on OneDayMD (CEBM Levels 1–5)

Every drug on this hub is tiered with the network-standard Oxford CEBM-style scale. This replaces the earlier traffic-light (green/yellow/red) labels used on this page, so that scores are comparable across OneDayMD, SmartCancer.org and cancer.aestheticsadvisor.com.

LevelWhat it meansTypical sources
Level 1Highest certainty for a clinical endpointSystematic reviews or meta-analyses of RCTs; multiple concordant, well-powered RCTs
Level 2One good randomized trial (confirmation desirable) or very strong prospective dataA single phase 3 RCT; large prospective cohorts with consistent effects
Level 3Suggestive but vulnerable to biasRetrospective cohorts, case-control studies, post-hoc subgroups
Level 4Weak clinical signalCase series, case reports, small early-phase studies without clear efficacy
Level 5Hypothesis onlyIn-vitro and animal studies, mechanistic reasoning, expert opinion

Testimonials without reproducible, documented data sit below Level 4 and are not tiered. A negative high-level trial matters as much as a positive one: it lowers the credibility of weaker evidence pointing the other way.

Evidence at a Glance: All Drugs Compared

DrugOriginal useBest human evidence (Oct 2026)CEBM tierKey cautions
AspirinPain, cardiovascular preventionALASCCA phase 3 RCT: lower recurrence in PI3K-altered stage I–III colorectal cancerLevel 2 (one setting; ADD-ASPIRIN pending)Bleeding; benefit shown only in a biomarker-selected, post-surgery group
MetforminType 2 diabetesObservational risk-reduction signals; MA.32 RCT negative in early breast cancerLevel 3 (signal) / negative Level 2 RCTNot an established cancer therapy; GI effects, B12 depletion, rare lactic acidosis
StatinsHigh cholesterolObservational mortality-reduction signals; mixed trial resultsLevel 3Effect appears cancer- and statin-specific; muscle and liver effects
PropranololHypertension, anxietySmall series and early studies, mainly angiosarcomaLevel 4Low blood pressure and heart rate; interactions
MebendazoleHuman anthelminticPreclinical models; small early clinical studies; limited, mixed randomized dataLevel 4–5Not standard of care; dosing in cancer not established
IvermectinAntiparasiticExtensive preclinical work; small phase 1/2 immunotherapy-combination data; observational reportsLevel 4–5ASCO 2026 notice against use outside trials; dose-dependent toxicity; interactions
FenbendazoleVeterinary anthelminticCell and animal studies; case reports only; no completed human trialsLevel 5 (case reports Level 4)No human approval; liver injury reports; ASCO 2026 notice against use outside trials

Antiparasitic and Anthelmintic Agents

These drugs generate the most public interest and the most misinformation. Read this section alongside ASCO's notice above.

Fenbendazole

Original use: veterinary anthelmintic (no human approval). CEBM tier: Level 5 for mechanisms; case reports Level 4.

Proposed mechanisms: microtubule destabilization, impaired glucose uptake, mitochondrial stress.

  • Cell-culture and animal data exist.
  • Human evidence is limited to case reports and self-reported use, usually alongside conventional treatment, which makes attribution unreliable.
  • There are no completed randomized human cancer trials.
  • A fenbendazole case series co-authored by Dr. William Makis was retracted in January 2026, a reminder to read the source behind any compiled “success story” list.

Key risks: no established human dosing, hepatotoxicity reports (including newly reported case reports of liver injury with ivermectin plus fenbendazole), unknown long-term safety, and variable quality of non-pharmaceutical products. Fenbendazole remains hypothesis-generating only.

Mebendazole

Original use: human antiparasitic. CEBM tier: Level 4–5.

Proposed mechanisms: tubulin inhibition, anti-angiogenesis, Hedgehog pathway interference.

  • Multiple preclinical cancer models, including brain tumor models.
  • Small early clinical studies in glioma and other tumors, with a generally favorable short-term safety profile.
  • Randomized evidence is limited and mixed; none has made mebendazole standard of care.

Mebendazole is among the more biologically plausible repurposed candidates, but plausibility is not proof, and it is not a substitute for proven therapy.

Ivermectin

Original use: antiparasitic. CEBM tier: Level 4–5.

Proposed mechanisms: inhibition of WNT/β-catenin signaling, mitochondrial dysfunction, immunomodulation.

  • Preclinical: an extensive oncology literature, much of it at concentrations that may be hard to reach safely in people.
  • Early clinical: a phase 1/2 study of ivermectin with the PD-1 inhibitor balstilimab in metastatic triple-negative breast cancer (Cedars-Sinai, NCT05318469) reported 2025 ASCO data in 8 evaluable patients: 1 partial response, 1 stable disease and 6 progressive disease, with the combination described as safe and well tolerated. That is a feasibility signal, not proof of efficacy.
  • Observational: a 197-patient cohort of people who obtained off-label ivermectin and mebendazole (Hulscher et al., Anticancer Research) drew an Expression of Concern from the journal in June 2026, and one author disclosed a conflict of interest with The Wellness Company. Only 122 of the 197 enrolled completed follow-up, and self-reported outcomes cannot establish causation.
  • Upcoming: the ICONIC trial (NCT07487805, University of Florida) was listed as not yet recruiting at the last check in September 2026. Verify current status on ClinicalTrials.gov.

Caution: toxicity is dose-dependent, ivermectin is processed through CYP3A4 and P-glycoprotein (shared with many cancer drugs), and neurotoxicity risk rises when P-glycoprotein is inhibited. Extrapolating beyond approved doses carries real risk.

Disclosure on named protocols. OneDayMD publishes articles on protocols associated with individual clinicians. Dr. William Makis's Alberta medical permit has been inactive since 2019 and a March 2026 court order permanently bars him from practicing medicine or using the titles “Dr.” or “oncologist”; an appeal was declined. Readers should weigh any protocol attributed to him accordingly. See our protocol article and patient-outcome table for the full context.

Metabolic and Endocrine Modulators

Metformin

Original use: type 2 diabetes. CEBM tier: Level 3 for observational risk signals; a large negative Level 2 RCT in early breast cancer.

Mechanisms: AMPK activation, mTOR suppression, lower insulin and IGF-1.

  • Observational studies, mostly in people with diabetes, link metformin to lower cancer incidence and mortality.
  • The CCTG MA.32 trial randomized 3,649 non-diabetic patients with high-risk early breast cancer to metformin or placebo and found no improvement in invasive disease-free survival (hazard ratio 1.01, 95% CI 0.84–1.21; JAMA 2022), nor in overall survival.
  • Other cancer-specific trials continue, and benefit in metabolically defined subgroups remains a hypothesis.

An earlier version of this page described metformin as a leading repurposing success story. In light of MA.32, a more accurate description is a strong hypothesis that has not been confirmed in its largest randomized test. Metformin is prescribed for diabetes and prediabetes on its own merits and should not be started for cancer without medical advice.

Statins

Original use: high cholesterol. CEBM tier: Level 3.

Mechanisms: mevalonate pathway inhibition and reduced prenylation of oncogenic proteins.

  • Strong observational signals of lower cancer-specific mortality in some cohorts.
  • Randomized results are mixed, and benefit appears context-dependent by cancer type and statin class.

Patients who already take a statin for cardiovascular reasons should not stop it on the basis of cancer headlines, and should not start one solely for cancer without physician guidance.

GLP-1 medicines and cancer

GLP-1 receptor agonists are being studied for obesity-related cancer risk and cancer outcomes. For the current data, see High-Evidence Repurposed Drugs & GLP-1 Oncology.

Aspirin and Anti-Inflammatory Agents

CEBM tier: Level 2 in one defined setting; otherwise Level 3.

Mechanisms: COX-2 inhibition, reduced platelet-mediated metastasis signaling, interaction with PI3K-pathway biology.

  • ALASCCA (Martling et al., NEJM, September 2025): 626 patients with stage I–III rectal or stage II–III colon cancer whose tumors carried PI3K-pathway alterations took aspirin 160 mg daily or placebo for 3 years. In the primary group (PIK3CA exon 9 or 20 hotspot mutations), 3-year recurrence was 7.7% with aspirin versus 14.1% with placebo (hazard ratio 0.49). Patients with other PI3K-pathway alterations had a similar benefit (7.7% versus 16.8%, hazard ratio 0.42).
  • Safety signal: severe adverse events occurred in 16.8% of aspirin recipients versus 11.6% on placebo, so bleeding and other harms are real trade-offs.
  • ADD-ASPIRIN (breast, colorectal, gastro-oesophageal and prostate cohorts; 100 mg or 300 mg versus placebo) lists a late-2026 completion date, and primary results had not been published when this page was updated.

The practical lesson is precision: ALASCCA tested aspirin in tumors selected by genomic markers, after surgery, under a research protocol. It does not show that everyone with cancer, or everyone worried about cancer, should take aspirin. People with bleeding risk, ulcers, anticoagulant use or upcoming procedures need individual medical advice.

Propranolol and Anti-Angiogenic Approaches

Original use: beta-blocker. CEBM tier: Level 4.

Mechanisms: suppression of stress-hormone signaling and angiogenesis.

  • Small case series and early-phase studies, mainly in angiosarcoma, suggest activity, which is why this page previously described the data as strong; they are better described as encouraging but preliminary.
  • Further studies in breast cancer and melanoma are ongoing.

Propranolol lowers blood pressure and heart rate and interacts with several drugs, so it needs medical supervision.

Repurposed Drugs vs Standard Oncology Care

Critical principle: repurposed drugs are adjunctive candidates, not replacements for surgery, radiation, chemotherapy, targeted therapy or immunotherapy.

Settings in which repurposed drugs are actually studied:

  • Adjuvant or maintenance therapy after curative treatment (aspirin in colorectal cancer is the leading example).
  • Treatment-resistant disease, usually inside clinical trials.
  • Combination with immunotherapy (for example ivermectin with checkpoint inhibitors).
  • Risk reduction and recurrence prevention.

The most serious risk of unsupervised use is opportunity cost: delaying or replacing treatment that has proven survival benefit.

Integrative Oncology: Where It Fits

Integrative cancer care complements standard treatment with:

  • Evidence-based lifestyle interventions and nutritional optimization
  • Exercise oncology
  • Selected supplements with mechanistic rationale and checked interactions
  • Psychosocial support and stress modulation

Not integrative oncology:

  • Abandoning proven treatments
  • Relying solely on anecdotes
  • Ignoring toxicity and drug interactions

Safety, Ethics and Regulatory Reality

Off-label use

  • Legal when physician-directed, but it requires informed consent.
  • Pharmaceutical-company liability and post-marketing oversight for the new use are absent.
  • Veterinary-grade and online-sourced products may have inconsistent purity and strength.

Key risks

  • Drug–drug interactions, including CYP3A4 and P-glycoprotein effects that can raise exposure to chemotherapy, targeted agents or the repurposed drug itself.
  • Organ toxicity, especially liver injury and, with some agents, neurotoxicity.
  • False hope and treatment delay.
  • Misinformation ecosystems that repeat retracted or contested studies.

Ethical standard

Any exploration of repurposed drugs should include transparent disclosure of uncertainty, continuous reassessment, disclosure of conflicts of interest, and alignment with the patient's values and their oncology team's plan.

Repurposed Drugs Are Entering the Precision Oncology Era

Drug repurposing historically relied on epidemiological observations, laboratory studies and anecdotal clinical signals. The field is now moving toward precision repurposing: matching an existing drug to a tumor's biology using AI-driven discovery, multi-omics, organoid testing and single-cell sequencing.

Hypotheses being explored (not established practice) include:

  • Aspirin in PI3K-pathway-altered colorectal cancer, the one example with phase 3 randomized support.
  • Metformin in insulin-resistant or metabolically dysregulated tumors.
  • Mebendazole in cancers dependent on microtubule signaling.
  • Ivermectin in tumors with WNT/β-catenin activation.
  • Statins in mevalonate-pathway-driven cancers.
  • Propranolol in stress-signaling and angiogenesis-driven tumors.

The shift is from “one repurposed drug for all cancers” to “the right drug for the right biological context,” and ALASCCA shows why: the average effect across all colorectal cancers would have hidden the benefit in the molecular subgroup.

Read more: Cancer Biomarker Map for Fenbendazole, Mebendazole and Ivermectin, a comparative mechanistic analysis for precision oncology (2026).

The Role of AI and In-Silico Trials

AI is accelerating repurposing by recognizing patterns in large datasets, matching drugs to pathways, and simulating virtual trials. It can analyze genomic data, pathology slides, molecular pathways, drug interactions and real-world outcomes to surface combinations no one has tested. This matters because conventional randomized trials cannot test every combination of targeted therapy, immunotherapy, metabolic therapy, diet, supplements and off-patent drugs.

The limits are equally important:

  • AI does not replace human trials; it helps decide which trials to run.
  • Bias, poor data quality and confident-sounding errors remain.
  • An AI ranking of “best” cancer drugs is a snapshot of its training data and prompt, not a clinical recommendation.

See also: AI Drug Repurposing: How Artificial Intelligence Finds New Uses for Old Drugs.

Who Should (and Should Not) Act on This Information

This hub is useful if you are:

  • A patient or caregiver preparing for an informed conversation with your oncology team
  • A clinician exploring adjunctive research responsibly
  • A researcher or analyst studying low-cost oncology strategies

Who should not self-prescribe:

  • Newly diagnosed patients who have not consulted an oncologist
  • Anyone delaying or declining curative treatment
  • Anyone on chemotherapy, targeted therapy, immunotherapy, anticoagulants or other interacting drugs without their team's knowledge

This page is not a substitute for oncology consultation, individualized treatment decisions, or emergency or curative care.

Questions to Bring to Your Oncologist

  1. What is the evidence level for this drug in my cancer type and stage, and is it from a randomized trial?
  2. Could it interact with my current chemotherapy, targeted therapy, immunotherapy or other medicines?
  3. Are there blood tests, such as liver or kidney function, I should have before and during use?
  4. Is there a clinical trial of this drug or a related one that I could join?
  5. Does my tumor have a molecular marker (for example a PI3K-pathway alteration) that changes which options make sense?
  6. If I decide to try it, how will we monitor benefit and harm, and what would make us stop?

Bottom Line

Repurposed drugs are a legitimate research frontier, not a miracle cure. In 2026 the evidence sorts into three groups:

  • Moving toward practice in narrow settings: aspirin in biomarker-selected colorectal cancer, pending confirmation and guideline review.
  • Promising but unconfirmed or disappointing in trials: metformin and statins, where observational signals have not translated cleanly.
  • Speculative and cautioned against outside trials: ivermectin and fenbendazole (ASCO, May 2026), with mebendazole between plausible and unproven.

Responsible engagement requires evidence literacy, humility, open conversations with your oncology team, and strict adherence to ethical medical practice. This pillar is the foundation for all repurposed-oncology content on OneDayMD.

Start Here: Core Guides and Deep Dives

Foundational guides

Drug-specific deep dives

AI Personalization Guide: Using Claude, ChatGPT, Gemini and Perplexity Wisely

Many readers now research cancer questions with AI assistants. Used well, they can help you organize questions and read papers. Used poorly, they can sound authoritative while being wrong or out of date. These tips apply to all of them.

AssistantUseful forWatch out for
ClaudeReading and summarizing long trial papers, comparing evidence levels, drafting a question list for your oncologistAsk it to separate what the trial showed from what it concluded; check any dates and trial status
ChatGPTPlain-language explanations, preparing visit notes, organizing a medication and supplement listConfident summaries of preclinical studies as if they were human evidence
GeminiCross-checking topics across web sources and organizing researchVerify trial identifiers and results on the original registry or journal page
PerplexityFinding sources quickly with linked citationsOpen the citations; low-quality or promotional pages can be cited alongside good ones

Copy-and-paste prompt

“I am discussing [drug name] with my oncologist for [cancer type, stage, current treatment]. Using only randomized trials and guidelines, tell me the evidence level (CEBM 1–5) for this exact setting, known interactions with [my current medicines], and what ASCO or NCCN says. Separate human data from lab and animal data. List the questions I should ask my care team. Do not give me a dose.”

  • Never ask an AI for a personal dose or to replace your oncologist's judgment.
  • Always confirm trial status on ClinicalTrials.gov and primary results in the journal.
  • If two assistants disagree, treat that as a prompt to ask your clinician, not to pick the answer you prefer.

Frequently Asked Questions

What are repurposed drugs in cancer care?

Existing approved medicines, originally developed for other conditions, that are being studied for anti-cancer effects. They are investigated as adjuncts to standard oncology care, not replacements for surgery, radiation, chemotherapy, targeted therapy or immunotherapy.

Which repurposed cancer drug has the strongest evidence in 2026?

Aspirin has the strongest recent randomized evidence in a defined setting: the ALASCCA phase 3 trial (NEJM, 2025) found that low-dose aspirin for 3 years reduced recurrence in stage I–III colorectal cancer with PI3K-pathway alterations. It is a biomarker-selected, post-surgery finding, and the larger ADD-ASPIRIN trial has not yet reported primary results.

Does metformin treat or prevent cancer recurrence?

Observational studies link metformin to lower cancer risk, but the large randomized MA.32 trial (3,649 patients) found no improvement in invasive disease-free survival when metformin was added to standard treatment for early breast cancer (hazard ratio 1.01). Metformin is not an established cancer treatment.

Does ASCO recommend ivermectin or fenbendazole for cancer?

ASCO's May 2026 Clinical Notice recommends against using ivermectin or fenbendazole to treat cancer outside a well-designed clinical trial, citing lack of human efficacy data, safety concerns at high doses, drug-interaction risks and the opportunity cost of delaying effective treatment.

Is mebendazole proven to work against cancer?

No. Mebendazole has plausible mechanisms and preclinical support, and small early clinical studies exist, but randomized evidence is limited and mixed. It is not standard of care for any cancer.

Can I take repurposed drugs together with chemotherapy or immunotherapy?

Only with your oncology team's knowledge. Some agents, including ivermectin and fenbendazole, are processed through CYP3A4 and P-glycoprotein pathways shared by many cancer drugs, so interactions and added toxicity are possible. Never add or stop a drug without telling your oncologist.

What is precision repurposing?

Using tumor biology, such as genomic markers, metabolic state or pathway activation, to decide which existing drug might suit which patient. The ALASCCA aspirin result in PI3K-altered colorectal cancer is the clearest current example.

How should I discuss repurposed drugs with my oncologist?

Bring a complete list of what you take or are considering, ask what evidence level supports each item for your cancer type and stage, ask about interactions with your current regimen, and ask whether a clinical trial is available. Do not delay or replace standard treatment.

Disclosures and Medical Disclaimer

Affiliate disclosure. OneDayMD participates in the affiliate programs of The Wellness Company (referral code ONEDAYMD) and Amazon Associates, and may earn a commission on qualifying purchases made through links on this network at no extra cost to you. Affiliate relationships do not influence our evidence tiering.

Medical disclaimer. This article is educational and is not medical advice, diagnosis or treatment. Off-label use of any drug for cancer should occur only under the supervision of a qualified physician, ideally within a clinical trial. Do not start, stop or change any treatment based on this page. If you are experiencing a medical emergency, contact your local emergency services.

Editorial note. Evidence reviewed through October 6, 2026. Trial statuses and regulatory positions change; verify on ClinicalTrials.gov and ASCO before acting.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer: Dr. William Makis Protocol Explained (2026 Guide)

Image
Medically Reviewed by: Dr. Frank Yap, MD  |  Written by: OneDayMD Editorial Team  |  Last Updated: September 2026 Important Disclaimer: This article is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer in the protocols described below; none is an FDA-approved cancer treatment. Do not self-medicate without bloodwork and physician supervision. Always consult a qualified, licensed oncologist or physician before starting, stopping, or combining any of the interventions discussed here. Quick Answer (AI & Search Summary) Dr. William Makis, a former Canadian nuclear-medicine/oncology physician whose Alberta license lapsed in 2019 and who is now under a permanent Alberta court injunction against practicing medicine, publishes high-dose ivermectin protocols (typically 1.0–2.0 mg/kg/day) combined with benzimidazoles (fenbendazole and/or mebendazole) for cance...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

Image
Quick Answer The supplements with the strongest human research behind them are vitamin D3 (paired with K2 and magnesium) , curcumin , omega-3 fatty acids , and green tea EGCG — each backed by multiple randomized controlled trials or meta-analyses, though results are mixed rather than uniformly positive. Melatonin looked promising in older, smaller trials, but the largest randomized trial to date found no overall survival benefit. No supplement replaces conventional cancer treatment, and a few — high-dose beta-carotene, vitamin E, and high-dose B6/B12 — have been linked to increased cancer risk in specific groups. Antioxidant supplements are generally discouraged during chemotherapy or radiotherapy unless a doctor directs otherwise. This is an educational overview, not personal medical advice — always loop in your oncology team before starting anything new. Disclosure: Some links in this article are affiliate links (including The Wellness Company and Amazon Associates). If ...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: August 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the precl...
Read more

Fenbendazole and the Joe Tippens Protocol (2026): Evidence, Risks, and Current Perspective

Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated: September 2026 Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are l...
Read more

Dr. William Makis's Recommended Ivermectin, Fenbendazole and Mebendazole Dosages for Cancer (2026)

Image
Last revised: August 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published...
Read more

New Cancer Treatment Breakthroughs 2026: Immunotherapy, AI, Cancer Vaccines & Beyond

Image
Medically Reviewed by: OneDayMD Editorial Team | Written by:     Dr Frank Yap, MD | Last Updated: August  2026 Quick Answer The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress is driven by combining precision diagnostics, immunotherapy, and targeted agents — not a single cure. Cancer remain...
Read more

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

30 Best Alternative and Repurposed Cancer Treatments: Evidence Based Literature Review (2026 Update)

Image
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 (v2.1) This article has been reorganised to rank all 30 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy. ⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024 Introduction Most mainstream guides to “alternative ca...
Read more

Top Cancer Drug & Biotech Companies in 2026: Oncology Leaders, Gene Therapy & Next-Generation Cancer Treatment

OneDayMD Oncology Intelligence • 2026 Update From Keytruda and CAR-T to antibody-drug conjugates, radioligand therapy and Gendicine gene therapy. Reviewed/updated: September 2026 The global cancer-treatment industry is entering a new era. Oncology is no longer defined simply by chemotherapy and conventional small-molecule drugs. The modern cancer-treatment ecosystem includes immune checkpoint inhibitors, targeted therapies, antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T cells, radioligand therapies, protein degraders, cancer vaccines, oncolytic viruses and gene therapies. This updated 2026 review therefore looks beyond a simple sales ranking. It evaluates the world's leading cancer-drug and biotechnology companies according to oncology commercial scale, therapeutic innovation, pipeline strength, platform technology, strategic importance and potential influence on the future of cancer treatment . Key takeaway: ...
Read more

Cancer Prevention Supplements & Diet: The I-PREVENT + ROOT Protocol (2026)

Image
Quick Answer: This framework merges OneDayMD's I-PREVENT Cancer Protocol with Dr. Paul Marik and Dr. Justus Hope's ROOT Protocol into a single five-layer system. Layer 1 is diet, metabolic health, and lifestyle — the original I-PREVENT foundation. Layers 2–3 are food-derived nutraceuticals (EGCG, curcumin, vitamin D3, omega-3, berberine, sulforaphane, vitamin C, magnesium, zinc, garlic, melatonin, and more), graded from strongest human-trial evidence to broader supporting data. Layer 4 is an optional Aged Garlic Extract upgrade. Layer 5 is Root 9 — the prescription drugs celecoxib, ivermectin, and mebendazole — which both authors scope strictly to people with confirmed hereditary cancer syndromes under specialist supervision, not general use. This is a prevention framework for healthy adults, not a cancer treatment protocol. Medically reviewed and updated by the OneDayMD Editorial Team | Merged framework published July 12, 2026 | Synthesizes and supersedes two ...
Read more